Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4970553 | 1.00 | P2RX3 (1.00) | P2RX3P2RX2 | |
| SCHEMBL5004765 | 0.92 | P2RX3 (1.00) | P2RX3P2RX2 | |
| SCHEMBL5009655 | 0.92 | P2RX3 (1.00) | P2RX3P2RX2 | |
| SCHEMBL19364044 | 0.92 | P2RX3 (0.84) | P2RX3P2RX2 | |
| SCHEMBL4968747 | 0.88 | P2RX3 (1.00) | P2RX3P2RX2 | |
| SCHEMBL5004772 | 0.86 | P2RX3 (1.00) | P2RX3P2RX2 | |
| SCHEMBL1493948 | 0.86 | P2RX3 (0.75) | P2RX3P2RX2 | |
| SCHEMBL1493943 | 0.86 | P2RX3 (0.75) | P2RX3P2RX2 | |
| SCHEMBL5004776 | 0.86 | P2RX3 (1.00) | P2RX3P2RX2 | |
| SCHEMBL3922732 | 0.85 | P2RX3 (1.00) | P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025229484-A1 | PURINERGIC P2 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF CONGENITAL SIDEROBLASTIC ANEMIAS | UNIVERSITÀ DEGLI STUDI DI BARI ALDO MORO (IT) | 2025-11-06 | — | — | WO | claimed |
| EP-4426280-B1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA ALEXANDRE (CH) | 2026-03-18 | — | — | EP | disclosed |
| US-20260070915-A1 | SUBSTITUTED 7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINES AS SELECTIVE CDK2/4 INHIBITORS | INCYTE CORP (US) | 2026-03-12 | — | — | US | disclosed |
| WO-2025229484-A1 | PURINERGIC P2 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF CONGENITAL SIDEROBLASTIC ANEMIAS | UNIVERSITÀ DEGLI STUDI DI BARI ALDO MORO (IT) | 2025-11-06 | — | — | WO | disclosed |
| CN-119676861-A | Communication method, device and storage medium | 展讯半导体(南京)有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20250057791-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA ALEXANDRE (CH) | 2025-02-20 | — | — | US | disclosed |
| US-20240408211-A1 | COMPOSITIONS AND METHODS OF AMELIORATING AVERSIVENESS OF AVERSIVE STIMULI BY INHIBITION OF PURINERGIC RECEPTORS | BRESLIN PAUL (US) | 2024-12-12 | — | — | US | disclosed |
| CN-118741746-A | Communication method and related device | 展讯半导体(南京)有限公司 | 2024-10-01 | — | — | CN | disclosed |
| EP-4426280-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | Gurba, Alexandre (CH) | 2024-09-11 | — | — | EP | disclosed |
| US-20240084305-A1 | MODULATORS OF CELL PROLIFERATION AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-03-14 | — | — | US | disclosed |
| WO-2023111938-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA, Alexandre (CH) | 2023-06-22 | — | — | WO | disclosed |
| EP-4197533-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | Guerin, Patrick (CH) | 2023-06-21 | — | — | EP | disclosed |
| US-20230013419-A1 | ANALOGUES OF 3-(5-METHYL-1,3-THIAZOL-2-YL)-N-{(1R)-1-[2-(TRIFLUORO-METHYL)PYRIMIDIN-5-YL]ETHYL}BENZAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-19 | — | — | US | disclosed |
| US-20230001008-A1 | COMPOSITIONS AND METHODS FOR TARGETING CELLULAR MOLECULES | KUMQUAT BIOSCIENCES INC. | 2023-01-05 | — | — | US | disclosed |
| WO-2022253943-A1 | CRYSTALLINE FORMS OF 3-(5-METHYL-1,3-THIAZOL-2-YL)-5-[(3R)-TETRAHYDROFURAN-3-YLOXY]-N-{(1R)-1-[2-(TRIFLUORO-METHYL)PYRIMIDIN-5-YL]ETHYL}-BENZAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022175514-A1 | N-(PYRIDIN-2-YL)-ACETAMIDES AS P2X3 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-08-25 | — | — | WO | disclosed |
| US-20220160714-A1 | METHODS FOR TREATING COLORECTAL CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2022-05-26 | — | — | US | disclosed |
| EP-3990453-A1 | ANALOGUES OF 3-(5-METHYL-1,3-THIAZOL-2-YL)-N-{(1R)-1-[2-(TRIFLUORO-METHYL)PYRIMIDIN-5-YL]ETHYL}BENZAMIDE | Bayer Aktiengesellschaft (DE) | 2022-05-04 | — | — | EP | disclosed |
| WO-2022076917-A1 | MODULATORS OF CELL PROLIFERATION AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-11278504-B1 | Treatment of a lionfish sting and formulations for use thereof | PTERO TECH INC. (CA) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230001008-A1 | COMPOSITIONS AND METHODS FOR TARGETING CELLULAR MOLECULES | CD2BP2, CD47, CD74 | P2RX3 4435/4885P2RX2 4446/4885 |
| US-20260070915-A1 | SUBSTITUTED 7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINES AS SELECTIVE CDK2/4 INHIBITORS | CDK4, CDK2, CCNC | P2RX3 3938/4885P2RX2 3991/4885 |
| US-11278504-B1 | Treatment of a lionfish sting and formulations for use thereof | P2RX3, P2RX7, P2RX5 | P2RX3 1/4885P2RX2 6/4885 |
| US-20240408211-A1 | COMPOSITIONS AND METHODS OF AMELIORATING AVERSIVENESS OF AVERSIVE STIMULI BY INHIBITION OF PURINERGIC RECEPTORS | P2RX3, P2RX2, P2RX6 | P2RX3 1/4885P2RX2 2/4885 |
| US-20240084305-A1 | MODULATORS OF CELL PROLIFERATION AND USES THEREOF | MKI67, MYC, CCNK | P2RX3 4562/4885P2RX2 4240/4885 |
| US-20230013419-A1 | ANALOGUES OF 3-(5-METHYL-1,3-THIAZOL-2-YL)-N-{(1R)-1-[2-(TRIFLUORO-METHYL)PYRIMIDIN-5-YL]ETHYL}BENZAMIDE | P2RX3, P2RX5, P2RX1 | P2RX3 1/4885P2RX2 4/4885 |
| US-20250057791-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | P2RX2, P2RX3, P2RX1 | P2RX3 2/4885P2RX2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.